MedPath

深圳翰宇药业股份有限公司

🇨🇳China
Ownership
-
Established
2003-04-02
Employees
429
Market Cap
-
Website
www.hybio.com.cn
Introduction

The company was founded in April 2003 and is a national high-tech enterprise specializing in research, production and marketing of peptide drugs. The company was listed on the Shenzhen Stock Exchange in 2011 and is the earliest listed peptide pharmaceutical company in China. The company's main business is the production and sale of peptide APIs. The company's main products include peptide preparations, peptide raw materials, customer-specific peptides, cosmetic peptides, solid pharmaceutical preparations, medical devices, peptide skin care products, health products, etc. Company Honors: National High-tech Enterprise, National Advanced Technology Industrialization Demonstration Project, 2010 China's Top 200 Potential Enterprises, etc.

Clinical Trials

0

Active:0
Completed:0

Trial Phases

0 Phases

Drug Approvals

63

NMPA:63

Drug Approvals

Exenatide Injection

Product Name
艾塞那肽注射液
Approval Number
国药准字H20244873
Approval Date
Sep 10, 2024
NMPA

Exenatide Injection

Product Name
艾塞那肽注射液
Approval Number
国药准字H20244874
Approval Date
Sep 10, 2024
NMPA

Ganirelix Acetate Injection

Product Name
醋酸加尼瑞克注射液
Approval Number
国药准字H20243797
Approval Date
May 21, 2024
NMPA

Terlipressin for Injection

Product Name
注射用特利加压素
Approval Number
国药准字H20093804
Approval Date
Mar 4, 2024
NMPA

Thymalfasin for Injection

Product Name
注射用胸腺法新
Approval Number
国药准字H20193037
Approval Date
Nov 27, 2023
NMPA

Terlipressin Injection

Product Name
特利加压素注射液
Approval Number
国药准字H20233111
Approval Date
May 26, 2023
NMPA

Oxytocin Injection

Product Name
缩宫素注射液
Approval Number
国药准字H20237032
Approval Date
Mar 26, 2023
NMPA

Sitagliptin Phosphate and metformin Hydrochloride Tablets(Ⅱ)

Product Name
西格列汀二甲双胍片(Ⅱ)
Approval Number
国药准字H20233025
Approval Date
Jan 10, 2023
NMPA

Vildagliptin Tablets

Product Name
维格列汀片
Approval Number
国药准字H20223927
Approval Date
Dec 30, 2022
NMPA

Pramipexole Dihydrochloride Sustained Release Tablets

Product Name
盐酸普拉克索缓释片
Approval Number
国药准字H20213752
Approval Date
Sep 30, 2021
NMPA
  • Prev
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • Next

Clinical Trials

No trials found

News

No news found

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.